Daniel Gaudet

List of Publications by Year in descending order

258 papers	23,343 citations	10389 72 h-index	8396 147 g-index
269 all docs	269 docs citations	269 times ranked	21589 citing authors

#	Article	IF	Citations
1	The common PPARÎ³ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nature Genetics, 2000, 26, 76-80.	21.4	1,672
2	Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. New England Journal of Medicine, 2008, 358, 1431-1443.	27.0	1,180
3	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, The, 2018, 392, 1519-1529.	13.7	1,179
4	Hypertriglyceridemic Waist. Circulation, 2000, 102, 179-184.	1.6	916
5	Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2010, 375, 998-1006.	13.7	813
6	Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nature Genetics, 2001, 29, 223-228.	21.4	730
7	Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet, The, 2013, 381, 40-46.	13.7	624
8	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2015, 385, 331-340.	13.7	615
9	Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet, The, 2012, 380, 29-36.	13.7	527
10	Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nature Genetics, 2009, 41, 71-76.	21.4	448
11	Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. New England Journal of Medicine, 2015, 373, 438-447.	27.0	445
12	Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia. Circulation, 2002, 105, 2469-2475.	1.6	440
13	Evinacumab for Homozygous Familial Hypercholesterolemia. New England Journal of Medicine, 2020, 383, 711-720.	27.0	413
14	Targeting APOC3 in the Familial Chylomicronemia Syndrome. New England Journal of Medicine, 2014, 371, 2200-2206.	27.0	376
15	Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. New England Journal of Medicine, 2019, 381, 531-542.	27.0	359
16	Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Therapy, 2013, 20, 361-369.	4.5	336
17	Type 2 Diabetes Without the Atherogenic Metabolic Triad Does Not Predict Angiographically Assessed Coronary Artery Disease in Women. Diabetes Care, 2008, 31, 170-172.	8.6	308
18	Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategiesâ€”a consensus statement from the European Atherosclerosis Society. European Heart Journal, 2021, 42, 4791-4806.	2.2	303

#	Article	IF	Citations
19	Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. Journal of the American Heart Association, 2019, 8, e011662.	3.7	292
20	Haplotype Structure and Genotype-Phenotype Correlations of the Sulfonylurea Receptor and the Islet ATP-Sensitive Potassium Channel Gene Region. Diabetes, 2004, 53, 1360-1368.	0.6	284
21	Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia. Circulation, 2012, 126, 2283-2292.	1.6	271
22	ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. New England Journal of Medicine, 2017, 377, 296-297.	27.0	258
23	Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respiratory Medicine,the, 2021, 9, 924-932.	10.7	218
24	Gestational diabetes mellitus epigenetically affects genes predominantly involved in metabolic diseases. Epigenetics, 2013, 8, 935-943.	2.7	217
25	Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3140-3148.	3.6	198
26	Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease. Journal of the American College of Cardiology, 2014, 64, 2525-2540.	2.8	192
27	Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. European Heart Journal, 2020, 41, 3936-3945.	2.2	188
28	Evinacumab in Patients with Refractory Hypercholesterolemia. New England Journal of Medicine, 2020, 383, 2307-2319.	27.0	186
29	Evaluation of Common Variants in the Six Known Maturity-Onset Diabetes of the Young (MODY) Genes for Association With Type 2 Diabetes. Diabetes, 2007, 56, 685-693.	0.6	178
30	Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150Âmg Every Two Weeks Dosing from Phase 2) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	178
31	Prenatal Exposure to Maternal Cigarette Smoking and DNA Methylation: Epigenome-Wide Association in a Discovery Sample of Adolescents and Replication in an Independent Cohort at Birth through 17 Years of Age. Environmental Health Perspectives, 2015, 123, 193-199.	6.0	178
32	Genomewide Linkage Analysis of Stature in Multiple Populations Reveals Several Regions with Evidence of Linkage to Adult Height. American Journal of Human Genetics, 2001, 69, 106-116.	6.2	177
33	Rarity of antiâ€“3â€hydroxyâ€3â€methylglutarylâ€coenzyme A reductase antibodies in statin users, including those with selfâ€limited musculoskeletal side effects. Arthritis Care and Research, 2012, 64, 269-272.	3.4	177
34	Comprehensive Association Testing of Common Mitochondrial DNA Variation in Metabolic Disease. American Journal of Human Genetics, 2006, 79, 54-61.	6.2	173
35	5' Flanking Variants of Resistin Are Associated With Obesity. Diabetes, 2002, 51, 1629-1634.	0.6	158
36	A largely random AAV integration profile after LPLD gene therapy. Nature Medicine, 2013, 19, 889-891.	30.7	150

#	Article	IF	Citations
37	Effect of Alipogene Tiparvovec (AAV1-LPL^{S447X}) on Postprandial Chylomicron Metabolism in Lipoprotein Lipase-Deficient Patients. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1635-1644.	3.6	146
38	Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet, The, 2021, 398, 1713-1725.	13.7	142
39	Glycerol: a neglected variable in metabolic processes?. BioEssays, 2001, 23, 534-542.	2.5	139
40	Increased frequency of DRB1*11:01 in antiâ€“hydroxymethylglutarylâ€coenzyme A reductaseâ€“associated autoimmune myopathy. Arthritis Care and Research, 2012, 64, 1233-1237.	3.4	126
41	Gene therapy for lipoprotein lipase deficiency. Current Opinion in Lipidology, 2012, 23, 310-320.	2.7	124
42	Immune Responses to Intramuscular Administration of Alipogene Tiparvovec (AAV1-LPL^{S447X}) in a Phase II Clinical Trial of Lipoprotein Lipase Deficiency Gene Therapy. Human Gene Therapy, 2014, 25, 180-188.	2.7	118
43	Effect of Alirocumab on Lipoprotein(a) Over â‰¥1.5ÂYears (from the Phase 3 ODYSSEY Program). American Journal of Cardiology, 2017, 119, 40-46.	1.6	116
44	Contribution of abdominal obesity and hypertriglyceridemia to impaired fasting glucose and coronary artery disease. American Journal of Cardiology, 2002, 90, 15-18.	1.6	114
45	ABCA1gene promoter DNA methylation is associated with HDL particle profile and coronary artery disease in familial hypercholesterolemia. Epigenetics, 2012, 7, 464-472.	2.7	114
46	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes and Endocrinology,the, 2020, 8, 50-67.	11.4	114
47	Genes, maternal smoking, and the offspring brain and body during adolescence: Design of the Saguenay Youth Study. Human Brain Mapping, 2007, 28, 502-518.	3.6	113
48	Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atherosclerosis Supplements, 2010, 11, 55-60.	1.2	110
49	Hypertriglyceridemic waist: a simple clinical phenotype associated with coronary artery disease in women. Metabolism: Clinical and Experimental, 2012, 61, 56-64.	3.4	110
50	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 264-275.	11.4	109
51	Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. New England Journal of Medicine, 2020, 383, 1317-1327.	27.0	108
52	Arterial Pressure, Left Ventricular Mass, and Aldosterone in Essential Hypertension. Hypertension, 2001, 37, 845-850.	2.7	106
53	Association between the PPARÎ±-L162V polymorphism and components of the metabolic syndrome. Journal of Human Genetics, 2004, 49, 482-489.	2.3	105
54	HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology. Nature Reviews Cardiology, 2018, 15, 9-19.	13.7	105

#	Article	IF	Citations
55	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. Canadian Journal of Cardiology, 2018, 34, 1553-1563.	1.7	105
56	Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. Circulation, 2017, 136, 332-335.	1.6	103
57	Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. Journal of Clinical Lipidology, 2018, 12, 920-927.e4.	1.5	97
58	Efficacy and Safety of Alirocumab inÂAdults With Homozygous FamilialÂHypercholesterolemia. Journal of the American College of Cardiology, 2020, 76, 131-142.	2.8	96
59	Canadian Cardiovascular Society Position Statement onÂFamilial Hypercholesterolemia. Canadian Journal of Cardiology, 2014, 30, 1471-1481.	1.7	93
60	Relationships of Abdominal Obesity and Hyperinsulinemia to Angiographically Assessed Coronary Artery Disease in Men With Known Mutations in the LDL Receptor Gene. Circulation, 1998, 97, 871-877.	1.6	91
61	Adaptations of placental and cord bloodABCA1ÂDNA methylation profile to maternal metabolic status. Epigenetics, 2013, 8, 1289-1302.	2.7	86
62	Relation of the â€œHypertriglyceridemic Waistâ€•Phenotype to Earlier Manifestations of Coronary Artery Disease in Patients With Glucose Intolerance and Type 2 Diabetes Mellitus. American Journal of Cardiology, 2007, 99, 369-373.	1.6	84
63	A Common Variant of the FTO Gene Is Associated With Not Only Increased Adiposity but Also Elevated Blood Pressure in French Canadians. Circulation: Cardiovascular Genetics, 2009, 2, 260-269.	5.1	84
64	Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia. Circulation, 2017, 136, 359-366.	1.6	84
65	Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. Lipids in Health and Disease, 2015, 14, 8.	3.0	83
66	Role of Tumor Necrosis Factor-Î± Gene Locus in Obesity and Obesity-Associated Hypertension in French Canadians. Hypertension, 2000, 36, 14-19.	2.7	82
67	Effect of Vupanorsen on Nonâ€“High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70. Circulation, 2022, 145, 1377-1386.	1.6	81
68	Association of Specific LDL Receptor Gene Mutations With Differential Plasma Lipoprotein Response to Simvastatin in Young French Canadians With Heterozygous Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1007-1012.	2.4	80
69	Genetic Analysis of 103 Candidate Genes for Coronary Artery Disease and Associated Phenotypes in a Founder Population Reveals a New Association between Endothelin-1 and High-Density Lipoprotein Cholesterol. American Journal of Human Genetics, 2007, 80, 673-682.	6.2	79
70	Association Testing in 9,000 People Fails to Confirm the Association of the Insulin Receptor Substrate-1 G972R Polymorphism With Type 2 Diabetes. Diabetes, 2004, 53, 3313-3318.	0.6	78
71	Hyperaldosteronism and Hypertension. Hypertension, 2005, 45, 766-772.	2.7	78
72	Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. European Heart Journal, 2022, 43, 1401-1412.	2.2	78

#	Article	IF	Citations
73	Common Variants in the ENPP1 Gene Are Not Reproducibly Associated With Diabetes or Obesity. Diabetes, 2006, 55, 3180-3184.	0.6	76
74	Common Polymorphisms in the Promoter of the Visfatin Gene (PBEF1) Influence Plasma Insulin Levels in a French-Canadian Population. Diabetes, 2006, 55, 2896-2902.	0.6	76
75	Association Testing of Variants in the Hepatocyte Nuclear Factor 4Â Gene With Risk of Type 2 Diabetes in 7,883 People. Diabetes, 2005, 54, 886-892.	0.6	75
76	Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis. Human Gene Therapy, 2016, 27, 916-925.	2.7	75
77	Association of Common Variation in the HNF1Â Gene Region With Risk of Type 2 Diabetes. Diabetes, 2005, 54, 2336-2342.	0.6	73
78	Efficacy and Safety of Alirocumab 150Âmg Every 4ÂWeeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. Journal of the American Heart Association, 2016, 5, .	3.7	71
79	Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate. Journal of Human Genetics, 2004, 49, 424-432.	2.3	62
80	Simplified Canadian Definition for Familial Hypercholesterolemia. Canadian Journal of Cardiology, 2018, 34, 1210-1214.	1.7	62
81	Functional Variation in the Androgen-Receptor Gene Is Associated With Visceral Adiposity and Blood Pressure in Male Adolescents. Hypertension, 2010, 55, 706-714.	2.7	61
82	Glomerular Hyperfiltration in Hypertensive African Americans. Hypertension, 2000, 35, 822-826.	2.7	60
83	Prenatal Exposure to Maternal Cigarette Smoking, Amygdala Volume, and Fat Intake in Adolescence. JAMA Psychiatry, 2013, 70, 98.	11.0	60
84	Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2248-2260.	2.4	60
85	The effect of an apolipoprotein A-Iâ€“containing high-density lipoproteinâ€“mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia. American Heart Journal, 2015, 169, 736-742.e1.	2.7	59
86	Epipolymorphisms within lipoprotein genes contribute independently to plasma lipid levels in familial hypercholesterolemia. Epigenetics, 2014, 9, 718-729.	2.7	57
87	Glycerophosphocholine Metabolites and Cardiovascular Disease Risk Factors in Adolescents. Circulation, 2016, 134, 1629-1636.	1.6	55
88	Etiology and risk of lactescent plasma and severe hypertriglyceridemia. Journal of Clinical Lipidology, 2011, 5, 37-44.	1.5	54
89	Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials. International Journal of Cardiology, 2016, 223, 750-757.	1.7	54
90	Glycerol as a Correlate of Impaired Glucose Tolerance: Dissection of a Complex System by Use of a Simple Genetic Trait. American Journal of Human Genetics, 2000, 66, 1558-1568.	6.2	53

#	Article	IF	Citations
91	Systematic, Genome-Wide, Sex-Specific Linkage of Cardiovascular Traits in French Canadians. Hypertension, 2008, 51, 1156-1162.	2.7	53
92	Genetic Variation in the Familial Mediterranean Fever Gene (MEFV) and Risk for Crohn's Disease and Ulcerative Colitis. PLoS ONE, 2009, 4, e7154.	2.5	53
93	Association Studies of BMI and Type 2 Diabetes in the Neuropeptide Y Pathway: A Possible Role for NPY2R as a Candidate Gene for Type 2 Diabetes in Men. Diabetes, 2007, 56, 1460-1467.	0.6	52
94	Contribution of receptor negative versus receptor defective mutations in the LDL-receptor gene to angiographically assessed coronary artery disease among young (25â€“49 years) versus middle-aged (50â€“64 years) men. Atherosclerosis, 1999, 143, 153-161.	0.8	50
95	Sex Differences in the Contributions of Visceral and Total Body Fat to Blood Pressure in Adolescence. Hypertension, 2012, 59, 572-579.	2.7	50
96	Genome-Wide Scan for Loci of Adolescent Obesity and Their Relationship with Blood Pressure. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E145-E150.	3.6	50
97	Association Testing of the Protein Tyrosine Phosphatase 1B Gene (PTPN1) With Type 2 Diabetes in 7,883 People. Diabetes, 2005, 54, 1884-1891.	0.6	49
98	Dyslipidemia of Mothers With Familial Hypercholesterolemia Deteriorates Lipids in Adult Offspring. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2673-2677.	2.4	49
99	Cohort Profile: The Saguenay Youth Study (SYS). International Journal of Epidemiology, 2017, 46, dyw023.	1.9	47
100	Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe. Clinical Chemistry, 2018, 64, 355-362.	3.2	47
101	FTO, obesity and the adolescent brain. Human Molecular Genetics, 2013, 22, 1050-1058.	2.9	46
102	In Vivo Variability of TMA Oxidation Is Partially Mediated by Polymorphisms of the FMO3 Gene. Molecular Genetics and Metabolism, 2001, 73, 224-229.	1.1	45
103	Procedure to protect confidentiality of familial data in community genetics and genomic research. Clinical Genetics, 1999, 55, 259-264.	2.0	44
104	Epigenome-wide analysis in familial hypercholesterolemia identified new loci associated with high-density lipoprotein cholesterol concentration. Epigenomics, 2012, 4, 623-639.	2.1	44
105	Heritability Estimates of Obesity Measures in Siblings With and Without Hypertension. Hypertension, 2001, 38, 41-47.	2.7	43
106	Impact of adiponectin gene polymorphisms on plasma lipoprotein and adiponectin concentrations of viscerally obese men. Journal of Lipid Research, 2005, 46, 237-244.	4.2	42
107	Efficacy and safety of rosuvastatin therapy inÂchildren and adolescents with familial hypercholesterolemia: Results from the CHARONÂstudy. Journal of Clinical Lipidology, 2015, 9, 741-750.	1.5	42
108	Efficacy of Rosuvastatin in ChildrenÂWithÂHomozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. Journal of the American College of Cardiology, 2017, 70, 1162-1170.	2.8	42

#	Article	IF	Citations
109	Cardiovascular disease in familial hypercholesterolemia: Validation and refinement of the Montreal-FH-SCORE. Journal of Clinical Lipidology, 2017, 11, 1161-1167.e3.	1.5	42
110	SARSâ€“CoV-2 Receptor ACE2 Gene Is Associated with Hypertension and Severity of COVID 19: Interaction with Sex, Obesity, and Smoking. American Journal of Hypertension, 2021, 34, 367-376.	2.0	42
111	ADRB3 gene promoter DNA methylation in blood and visceral adipose tissue isÂassociated with metabolic disturbances in men. Epigenomics, 2014, 6, 33-43.	2.1	41
112	The potential applications of Apolipoprotein E in personalized medicine. Frontiers in Aging Neuroscience, 2014, 6, 154.	3.4	40
113	Mutations in the Gene for Lipoprotein Lipase. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1704-1712.	2.4	39
114	Visceral obesity attenuates the effect of the hepatic lipase â^'514C>T polymorphism on plasma HDL-cholesterol levels in French-Canadian men. Molecular Genetics and Metabolism, 2003, 78, 31-36.	1.1	39
115	Genome-Wide Scan for Linkage to Obesity-Associated Hypertension in French Canadians. Hypertension, 2005, 46, 1280-1285.	2.7	39
116	Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia. European Heart Journal, 2017, 38, ehw135.	2.2	38
117	Placental lipoprotein lipase DNA methylation alterations are associated with gestational diabetes and body composition at 5Âyears of age. Epigenetics, 2017, 12, 616-625.	2.7	38
118	Genetic mapping of habitual substance use, obesity-related traits, responses to mental and physical stress, and heart rate and blood pressure measurements reveals shared genes that are overrepresented in the neural synapse. Hypertension Research, 2012, 35, 585-591.	2.7	37
119	Epigenetic dysregulation of the IGF system in placenta of newborns exposed to maternal impaired glucose tolerance. Epigenomics, 2014, 6, 193-207.	2.1	37
120	Phosducin influences sympathetic activity and prevents stress-induced hypertension in humans and mice. Journal of Clinical Investigation, 2009, 119, 3597-3612.	8.2	37
121	Relative contribution of low-density lipoprotein receptor and lipoprotein lipase gene mutations to angiographically assessed coronary artery disease among French Canadians. American Journal of Cardiology, 1998, 82, 299-305.	1.6	36
122	Geographic distribution of Frenchâ€Canadian lowâ€density lipoprotein receptor gene mutations in the Province of Quebec. Clinical Genetics, 1997, 52, 1-6.	2.0	36
123	Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia. Journal of the American College of Cardiology, 2021, 78, 193-195.	2.8	36
124	Visceral obesity and hyperinsulinemia modulate the impact of the microsomal triglyceride transfer protein â^'493G/T polymorphism on plasma lipoprotein levels in men. Atherosclerosis, 2002, 160, 317-324.	0.8	35
125	Identification of a Novel C5L2 Variant (S323I) in a French Canadian Family With Familial Combined Hyperlipemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1619-1625.	2.4	35
126	Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy. Canadian Journal of Cardiology, 2017, 33, 872-882.	1.7	34

#	Article	IF	Citations
127	Variants within the muscle and liver isoforms of the carnitine palmitoyltransferase I (CPT1) gene interact with fat intake to modulate indices of obesity in French-Canadians. Journal of Molecular Medicine, 2007, 85, 129-137.	3.9	33
128	Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. Journal of the Endocrine Society, 2019, 3, 2397-2410.	0.2	32
129	Predictors of Target Organ Damage in Hypertensive Blacks and Whites. Hypertension, 2001, 38, 761-766.	2.7	31
130	Association of heterozygous familial hypercholesterolemia with smaller HDL particle size. Atherosclerosis, 2007, 190, 429-435.	0.8	31
131	Relationship between cholesteryl ester transfer protein and LDL heterogeneity in familial hypercholesterolemia. Journal of Lipid Research, 2004, 45, 1077-1083.	4.2	30
132	The DGAT1 Inhibitor LCQ908 Decreases Triglyceride Levels in Patients with the Familial Chylomicronemia Syndrome. Journal of Clinical Lipidology, 2012, 6, 266-267.	1.5	30
133	Dietâ€induced Obesity Delays Cardiovascular Recovery from Stress in Spontaneously Hypertensive Rats. Obesity, 2004, 12, 1951-1958.	4.0	28
134	Haplotype Structures and Large-Scale Association Testing of the 5' AMP-Activated Protein Kinase Genes PRKAA2, PRKAB1, and PRKAB2 With Type 2 Diabetes. Diabetes, 2006, 55, 849-855.	0.6	28
135	The lipoprotein/lipid profile is modulated by a geneâ€“diet interaction effect between polymorphisms in the liver X receptor-Î± and dietary cholesterol intake in French-Canadians. British Journal of Nutrition, 2007, 97, 11-18.	2.3	28
136	Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study -- Observational (CALIPSO). Canadian Journal of Cardiology, 2005, 21, 1187-93.	1.7	28
137	Prevalence of Lifestyle Risk Factors in Myotonic Dystrophy Type 1. Canadian Journal of Neurological Sciences, 2013, 40, 42-47.	0.5	27
138	Layered genetic control of DNA methylation and gene expression: a locus of multiple sclerosis in healthy individuals. Human Molecular Genetics, 2015, 24, 5733-5745.	2.9	26
139	Epigenetic and genetic variations at the TNNT1 gene locus are associated with HDL-C levels and coronary artery disease. Epigenomics, 2016, 8, 359-371.	2.1	26
140	Identification of three mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians. Human Mutation, 1998, 11, S226-S231.	2.5	25
141	Acute Pancreatitis is Highly Prevalent and Complications can be Fatal in Patients with Familial Chylomicronemia: Results From a Survey of Lipidologist. Journal of Clinical Lipidology, 2016, 10, 680-681.	1.5	25
142	LRP1B, BRD2 and CACNA1D: new candidate genes in fetal metabolic programming of newborns exposed to maternal hyperglycemia. Epigenomics, 2015, 7, 1111-1122.	2.1	24
143	Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study. Journal of Clinical Lipidology, 2018, 12, 1199-1207.	1.5	24
144	Segment of Rat Chromosome 20 Regulates Diet-Induced Augmentations in Adiposity, Glucose Intolerance, and Blood Pressure. Hypertension, 2003, 41, 1047-1055.	2.7	23

#	Article	IF	Citations
145	The approach study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). Atherosclerosis, 2017, 263, e10.	0.8	23
146	Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1). American Journal of Cardiology, 2019, 124, 1876-1880.	1.6	23
147	Routine Clinical Measures of Adiposity as Predictors of Visceral Fat in Adolescence: A Population-Based Magnetic Resonance Imaging Study. PLoS ONE, 2013, 8, e79896.	2.5	23
148	Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1-p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations. Atherosclerosis, 1999, 143, 145-151.	0.8	22
149	The c.419-420insA in the MTP gene is associated with abetalipoproteinemia among French-Canadians. Molecular Genetics and Metabolism, 2004, 81, 140-143.	1.1	22
150	Genetic Information and the Prediction of Incident Type 2 Diabetes in a High-Risk Multiethnic Population. Diabetes Care, 2013, 36, 2836-2842.	8.6	22
151	Large-scale deletions of the ABCA1 gene in patients with hypoalphalipoproteinemia. Journal of Lipid Research, 2018, 59, 1529-1535.	4.2	22
152	A Genealogical Study of Essential Hypertension with and without Obesity in French Canadians. Obesity, 2002, 10, 463-470.	4.0	21
153	No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. Atherosclerosis, 2020, 311, 13-19.	0.8	21
154	Transient expression of the Î²-glucuronidase gene in Cannabis sativa varieties. Plant Signaling and Behavior, 2020, 15, 1780037.	2.4	21
155	Lipoprotein lipase deficiency is associated with elevated acylation stimulating protein plasma levels. Journal of Lipid Research, 2009, 50, 1109-1119.	4.2	20
156	Prenatal exposure to cigarette smoke interacts with OPRM1 to modulate dietary preference for fat. Journal of Psychiatry and Neuroscience, 2015, 40, 38-45.	2.4	20
157	Visceral fat-related systemic inflammation and the adolescent brain: a mediating role of circulating glycerophosphocholines. International Journal of Obesity, 2019, 43, 1223-1230.	3.4	20
158	Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics. Pharmacogenetics and Genomics, 2010, 20, 742-747.	1.5	20
159	Gene-based therapies in lipidology. Current Opinion in Lipidology, 2015, 26, 553-565.	2.7	19
160	Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study. European Journal of Preventive Cardiology, 2022, 28, 1864-1872.	1.8	19
161	Low plasma adiponectin exacerbates the risk of premature coronary artery disease in familial hypercholesterolemia. Atherosclerosis, 2008, 196, 262-269.	0.8	18
162	Novel therapies for severe dyslipidemia originating from human genetics. Current Opinion in Lipidology, 2016, 27, 112-124.	2.7	18

#	Article	IF	Citations
163	Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment. International Journal of Cardiology, 2017, 228, 754-760.	1.7	18
164	Roundtable discussion: Familial chylomicronemia syndrome: Diagnosis and management. Journal of Clinical Lipidology, 2018, 12, 254-263.	1.5	18
165	Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry. Atherosclerosis, 2018, 277, 419-424.	0.8	18
166	Pharmacogenomics of statin-related myopathy: Meta-analysis of rare variants from whole-exome sequencing. PLoS ONE, 2019, 14, e0218115.	2.5	18
167	Identification of a chromosome 8p locus for early-onset coronary heart disease in a French Canadian population. European Journal of Human Genetics, 2008, 16, 105-114.	2.8	17
168	A study in familial hypercholesterolemia suggests reduced methylomic plasticity in men with coronary artery disease. Epigenomics, 2015, 7, 17-34.	2.1	17
169	The Kruppel-Like Factor 11 (KLF11) Q62R Polymorphism Is Not Associated With Type 2 Diabetes in 8,676 People. Diabetes, 2006, 55, 3620-3624.	0.6	16
170	Clustering of the Metabolic Syndrome Components in Adolescence: Role of Visceral Fat. PLoS ONE, 2013, 8, e82368.	2.5	16
171	Roundtable on etiology of familial chylomicronemia syndrome. Journal of Clinical Lipidology, 2018, 12, 5-11.	1.5	16
172	Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia. Expert Opinion on Drug Safety, 2019, 18, 403-414.	2.4	16
173	Immunosuppression Modulates Immune Responses to AAV Capsid in Human Subjects Undergoing Intramuscular Gene Transfer for Lipoprotein Lipase Deficiency. Blood, 2008, 112, 822-822.	1.4	16
174	Hypertriglyceridemia and Lower LDL Cholesterol Concentration in Relation to Apolipoprotein E Phenotypes in Myotonic Dystrophy. Canadian Journal of Neurological Sciences, 1989, 16, 129-133.	0.5	15
175	Molecular screening of the microsomal triglyceride transfer protein: association between polymorphisms and both abdominal obesity and plasma apolipoprotein B concentration. Journal of Human Genetics, 2004, 49, 684-690.	2.3	15
176	Fine mapping and association studies of a high-density lipoprotein cholesterol linkage region on chromosome 16 in French-Canadian subjects. European Journal of Human Genetics, 2010, 18, 342-347.	2.8	15
177	Design and baseline data of a pediatric study with rosuvastatin in familial hypercholesterolemia. Journal of Clinical Lipidology, 2013, 7, 408-413.	1.5	15
178	The burden of familial chylomicronemia syndrome in Canadian patients. Lipids in Health and Disease, 2020, 19, 120.	3.0	15
179	Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. Journal of Clinical Lipidology, 2022, 16, 617-625.	1.5	15
180	Salivary pH as a marker of plasma adiponectin concentrations in Women. Diabetology and Metabolic Syndrome, 2012, 4, 4.	2.7	14

#	Article	IF	Citations
181	Medical resource use and costs associated with chylomicronemia. Journal of Medical Economics, 2013, 16, 657-666.	2.1	14
182	Natural History (up to 15 years) of Platelet Count in 84 Patients with Familial Hyperchylomicronemia Due to Lipoprotein Lipase Deficiency. Journal of Clinical Lipidology, 2017, 11, 797-798.	1.5	14
183	A variant near DHCR24 associates with microstructural properties of white matter and peripheral lipid metabolism in adolescents. Molecular Psychiatry, 2021, 26, 3795-3805.	7.9	14
184	Dissection of Clinical and Gene Expression Signatures of Familial versus Multifactorial Chylomicronemia. Journal of the Endocrine Society, 2020, 4, bvaa056.	0.2	14
185	Effectiveness of a Novel Ï‰-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia. JAMA Network Open, 2022, 5, e2141898.	5.9	14
186	Treatment with Volanesorsen (VLN) Reduced Triglycerides and Pancreatitis in Patients with FCS and sHTG vs Placebo: Results of the APPROACH and COMPASS â€. Journal of Clinical Lipidology, 2018, 12, 537.	1.5	13
187	High-density haplotype structure and association testing of the insulin-degrading enzyme (IDE) gene with type 2 diabetes in 4,206 people. Diabetes, 2006, 55, 128-35.	0.6	13
188	Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE. Archives of Medical Science, 2022, 18, 285-292.	0.9	13
189	Characterization of LDL Particle Size Among Carriers of a Defective or a Null Mutation in the Lipoprotein Lipase Gene. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1181-1186.	2.4	12
190	Translating the Genomics Revolution: The Need for an International Gene Therapy Consortium for Monogenic Diseases. Molecular Therapy, 2013, 21, 266-268.	8.2	12
191	Lomitapide for treatment of homozygous familial hypercholesterolemia: The QuÃ©bec experience. Atherosclerosis, 2020, 310, 54-63.	0.8	12
192	Genetic burden linked to founder effects in Saguenayâ€“Lac-Saint-Jean illustrates the importance of genetic screening test availability. Journal of Medical Genetics, 2021, 58, 653-665.	3.2	12
193	Metabolic syndrome and oral markers of cardiometabolic risk. Journal of the Canadian Dental Association, 2011, 77, b125.	0.6	12
194	Association of CTRC and SPINK1 gene variants with recurrent hospitalizations for pancreatitis or acute abdominal pain in lipoprotein lipase deficiency. Frontiers in Genetics, 2014, 5, 90.	2.3	11
195	Novel Genetic Locus of Visceral Fat and Systemic Inflammation. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3735-3742.	3.6	11
196	Non-Alcoholic Fatty Liver in Patients with Chylomicronemia. Journal of Clinical Medicine, 2021, 10, 669.	2.4	11
197	Influence of Abdominal Obesity on the Lipid-Lipoprotein Profile in Apoprotein E2/4 Carriers: The Effect of an Apparent Duality. Journal of Lipids, 2015, 2015, 1-10.	4.8	10
198	A Sequence Variation in the Mitochondrial Glycerol-3-Phosphate Dehydrogenase Gene Is Associated with Increased Plasma Glycerol and Free Fatty Acid Concentrations among French Canadians. Molecular Genetics and Metabolism, 2001, 72, 209-217.	1.1	9

#	Article	IF	Citations
199	Genotype of the mutant LDL receptor allele is associated with LDL particle size heterogeneity in familial hypercholesterolemia. Atherosclerosis, 2006, 184, 163-170.	0.8	9
200	Apolipoprotein E and lipoprotein lipase gene polymorphisms interaction on the atherogenic combined expression of hypertriglyceridemia and hyperapobetalipoproteinemia phenotypes. Journal of Endocrinological Investigation, 2007, 30, 551-557.	3.3	9
201	A locus on chromosome 10 influences C-reactive protein levels in two independent populations. Human Genetics, 2007, 122, 95-102.	3.8	9
202	Decreased NKCC1 Activity in Erythrocytes From African Americans With Hypertension and Dyslipidemia. American Journal of Hypertension, 2010, 23, 321-326.	2.0	9
203	Angiographically-assessed coronary artery disease associates with HDL particle size in women. Atherosclerosis, 2012, 223, 359-364.	0.8	9
204	Deficient Cholesterol Esterification in Plasma of apoc2 Knockout Zebrafish and Familial Chylomicronemia Patients. PLoS ONE, 2017, 12, e0169939.	2.5	9
205	Adiposityâ€related insulin resistance and thickness of the cerebral cortex in middleâ€aged adults. Journal of Neuroendocrinology, 2020, 32, e12921.	2.6	9
206	Identifying Markers of Cardiovascular Event-Free Survival in Familial Hypercholesterolemia. Journal of Clinical Medicine, 2021, 10, 64.	2.4	9
207	Determinants of HDL particle size in patients with the null (P207L) or defective (D9N) mutation in the lipoprotein lipase gene: the QuÃ©bec LipD Study. Atherosclerosis, 2002, 162, 269-276.	0.8	8
208	Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia receiving concomitant lipid-lowering therapies. Journal of Clinical Lipidology, 2016, 10, 715.	1.5	8
209	Sex Differences in Blood Pressure Hemodynamics in Middle-Aged Adults With Overweight and Obesity. Hypertension, 2019, 74, 407-412.	2.7	8
210	DNA methylation at LRP1 gene locus mediates the association between maternal total cholesterol changes in pregnancy and cord blood leptin levels. Journal of Developmental Origins of Health and Disease, 2020, 11, 369-378.	1.4	8
211	Fine Mapping of the Insulin-Induced Gene 2 Identifies a Variant Associated With LDL Cholesterol and Total Apolipoprotein B Levels. Circulation: Cardiovascular Genetics, 2010, 3, 454-461.	5.1	7
212	Genetics of symptom remission in outpatients with COVID-19. Scientific Reports, 2021, 11, 10847.	3.3	7
213	Influence of the LDL-Receptor Genotype on Statin Response in Heterozygous Familial Hypercholesterolemia: Insights From the Canadian FH Registry. Canadian Journal of Cardiology, 2022, 38, 311-319.	1.7	7
214	A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting. Advances in Therapy, 2022, 39, 1857-1870.	2.9	7
215	Myotonic Dystrophy: Linkage with Apolipoprotein E and Estimation of the Gene Carrier Status with Genetic Markers. Canadian Journal of Neurological Sciences, 1989, 16, 134-140.	0.5	6
216	On-site management of investigational products and drug delivery systems in conformity with Good Clinical Practices (GCPs). Clinical Trials, 2012, 9, 265-271.	1.6	6

#	Article	IF	Citations
217	CYP17A1and Blood Pressure Reactivity to Stress in Adolescence. International Journal of Hypertension, 2015, 2015, 1-9.	1.3	6
218	Association between a polymorphic poly-T repeat sequence in the promoter of the somatostatin gene and hypertension. Hypertension Research, 2016, 39, 467-474.	2.7	6
219	Relative effect of hypertriglyceridemia on non-HDLC and apolipoprotein B as cardiovascular disease risk markers. Journal of Clinical Lipidology, 2020, 14, 825-836.	1.5	6
220	Development and Standardization of Rapid and Efficient Seed Germination Protocol for Cannabis sativa. Bio-protocol, 2021, 11, e3875.	0.4	6
221	K45R variant of squalene synthase increases total cholesterol levels in two study samples from a French Canadian population. Human Mutation, 2008, 29, 689-694.	2.5	5
222	Coronary Atheroma Regression From Infusions of Autologous Selectively Delipidated Preî²-HDL-Enriched Plasma in Homozygous Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2020, 76, 3062-3064.	2.8	5
223	Genetic aspects of diabetes and its cardiovascular complications: contribution of genetics to risk assessment and clinical management. Canadian Journal of Cardiology, 2005, 21, 199-209.	1.7	5
224	Contribution of adiponectin to the cardiometabolic risk of postmenopausal women with loss-of-function lipoprotein lipase gene mutations. Menopause, 2011, 18, 558-562.	2.0	4
225	Calculated Non-HDL Cholesterol Includes Cholesterol in Larger Triglyceride-Rich Lipoproteins in Hypertriglyceridemia. Journal of the Endocrine Society, 2020, 4, bvz010.	0.2	4
226	Genealogical analysis as a new approach for the investigation of drug intolerance heritability. European Journal of Human Genetics, 2014, 22, 916-922.	2.8	3
227	The Diacylglycerol Acyltransferase 1 Inhibitor, Pradigastat, Was Well Tolerated in a 52-Week Clinical Trial in FCS Patients. Journal of Clinical Lipidology, 2015, 9, 450.	1.5	3
228	Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study. Lipids in Health and Disease, 2020, 19, 117.	3.0	3
229	Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia. Expert Opinion on Drug Discovery, 2020, 15, 403-414.	5.0	3
230	Gene expression profiles of recurrent acute pancreatitis risk in patients with sustained chylomicronemia. Endocrine Journal, 2020, 67, 1157-1161.	1.6	3
231	Lessons learned from the evinacumab trials in the treatment of homozygous familial hypercholesterolemia. Future Cardiology, 2022, 18, 507-518.	1.2	3
232	Reply to: NGS library preparation may generate artifactual integration sites of AAV vectors. Nature Medicine, 2014, 20, 578-579.	30.7	2
233	Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm. CJC Open, 2019, 1, 190-197.	1.5	2
234	1.P.168 Abdominal obesity and hyperinsulinemia as predictors of higher cost of coronary artery bypass grafting among men with or without familial hypercholesterolemia. Atherosclerosis, 1997, 134, 52.	0.8	1

#	Article	IF	Citations
235	Presence of palmar xanthomas in myotonic dystrophy identifies different patterns of linkage disequilibrium between the apolipoprotein E and myotonic dystrophy protein kinase loci. Genetics in Medicine, 2005, 7, 213-215.	2.4	1
236	Gestational Diabetes Mellitus Epigenetically Predominantly Affects Genes Involved in Metabolic Diseases. Canadian Journal of Diabetes, 2013, 37, S241.	0.8	1
237	An Antisense Inhibitor of Apolipoprotein C-III Substantially Decreases Fasting Apolipoprotein C-III and Triglyceride Levels in LPL Deficiency. Journal of Clinical Lipidology, 2014, 8, 353-354.	1.5	1
238	Gene Expression Signature of Platelet Count in Lipoprotein Lipase Deficiency. Journal of Clinical Lipidology, 2017, 11, 795.	1.5	1
239	FIrst interim results of the global, longitudinal, pharmaco-epidemiologic, observational registry on gene therapy in the management of lipoprotein lipase deficiency (geniall). Atherosclerosis, 2017, 263, e66-e67.	0.8	1
240	Characterizing Familial Chylomicronemia Syndrome: Baseline data of the APPROACH Study. Journal of Clinical Lipidology, 2017, 11, 816.	1.5	1
241	Response by Kusters et al to Letter Regarding Article, â€œEffect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)â€. Circulation, 2018, 137, 641-642.	1.6	1
242	Association study between a polymorphic poly-T repeat sequence in the promoter of the somatostatin gene and metabolic syndrome. BMC Medical Genetics, 2018, 19, 130.	2.1	1
243	Correlation between chylomicronemia diagnosis scores and post-heparin lipoprotein lipase activity. Journal of Clinical Lipidology, 2019, 13, e25-e26.	1.5	1
244	Association of common gene-smoking interactions with elevated plasma apolipoprotein B concentration. Lipids in Health and Disease, 2020, 19, 98.	3.0	1
245	From Clinical Sites to Biorepositories: Effectiveness in Blood Sample Management. Biopreservation and Biobanking, 2010, 8, 193-196.	1.0	0
246	Lipoprotein Lipase Deficiency Clinical Biomarkers*. Journal of Clinical Lipidology, 2013, 7, 241.	1.5	0
247	Prenatal Exposure to Maternal Cigarette Smoking is Associated with Parasympathetic Predominance and Higher Dietary Fat Intake in Adolescence. Canadian Journal of Diabetes, 2013, 37, S266-S267.	0.8	0
248	Pradigastat Did Not Increase Fecal Bile Acids in Patients with Familial Chylomicronemia Syndrome After 52 Weeks. Journal of Clinical Lipidology, 2015, 9, 454-455.	1.5	0
249	Association Between Frequent Gene-Smoking Interactions And Plama Apolipoprotein B Levels Among Low-Risk Individuals. Journal of Clinical Lipidology, 2016, 10, 671-672.	1.5	0
250	Genetic and Functional investigation of LPL Independent Pathways of TG-Rich Lipoproteins Catabolism in Severe Hypertriglyceridemia and Chylomicronemia. Journal of Clinical Lipidology, 2016, 10, 664.	1.5	0
251	The odyssey apprise trial: rationale, design and interim data. Atherosclerosis, 2017, 263, e25.	0.8	0
252	Predicting Cardiovascular Events in Familial Hypercholesterolemia: Validation of the Montreal-FH-SCORE. Journal of Clinical Lipidology, 2017, 11, 781.	1.5	0

#	Article	IF	Citations
253	Surviving Familial Hypercholesterolemia without Coronary Artery Disease: A Unique Phenomenon Associated with Newly Identified Biological and Genetic Markers. Atherosclerosis Supplements, 2018, 32, 51.	1.2	0
254	Free glycerol correlate with post-heparin lipoprotein lipase activity and contribute to differentiate familial vs. multifactorial chylomicronemia. Journal of Clinical Lipidology, 2019, 13, e26.	1.5	0
255	Comparison of the Effect of Hypertriglyceridemia on Non-HDL-Cholesterol and Apolipoprotein B as Cardiovascular Disease Risk Markersâˆ—â€. Journal of Clinical Lipidology, 2020, 14, 571-572.	1.5	0
256	Phosducin influences sympathetic activity and prevents stress-induced hypertension in humans and mice. Journal of Clinical Investigation, 2011, 121, 454-454.	8.2	0
257	Lomitapide Reduces LDL-C and Favourably Affects Carotid Intima Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting. Journal of Clinical Lipidology, 2022, 16, e18-e19.	1.5	0
258	Palmar Striated Xanthomas in Clinical Practice. Journal of the Endocrine Society, 2022, 6, .	0.2	0